中生製藥(01177.HK)簽訂LAG3單克隆抗體收購協議 料6月完成交易
中生製藥(01177.HK)宣佈,附屬公司正大天晴藥業於5月18日與製藥公司施維雅旗下的Symphogen A/S簽訂協議,收購產品LAG3單克隆抗體Sym022。
該產品爲全人源重組的LAG-3單克隆抗體,於臨牀前階段展現出良好的腫瘤抑制潛力。中生製藥表示,目前該產品已完成兩項臨牀一期實驗,臨牀結果顯示具有良好的安全性和耐受性。
正大天晴將在交割時按照收購對價付款給Symphogen,同時該交易涉及銷售相關的潛在裏程碑付款,預期交易於今年6月完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.